Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease

Imagem de Miniatura
Arquivos
art_EHRENBERG_Neuropathologic_Correlates_of_Psychiatric_Symptoms_in_Alzheimers_Disease_2018.PDF (307.34 KB)
Citações na Scopus
128
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
IOS PRESS
Autores
EHRENBERG, Alexander J.
RESENDE, Elisa de Paula Franca
PETERSEN, Cathrine
YOU, Michelle
OH, Jun
Citação
JOURNAL OF ALZHEIMERS DISEASE, v.66, n.1, p.115-126, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Clarifying the relationships between neuropsychiatric symptoms and Alzheimer's disease (AD)-related pathology may open avenues for effective treatments. Here, we investigate the odds of developing neuropsychiatric symptoms across increasing burdens of neurofibrillary tangle and amyloid-beta pathology. Participants who passed away between 2004 and 2014 underwent comprehensive neuropathologic evaluation at the Biobank for Aging Studies from the Faculty of Medicine at the University of Sao Paulo. Postmortem interviews with reliable informants were used to collect information regarding neuropsychiatric and cognitive status. Of 1,092 cases collected, those with any non-Alzheimer pathology were excluded, bringing the cohort to 455 cases. Braak staging was used to evaluate neurofibrillary tangle burden, and the CERAD neuropathology score was used to evaluate amyloid-beta burden. The 12-item neuropsychiatric inventory was used to evaluate neuropsychiatric symptoms and CDR-SOB score was used to evaluate dementia status. In Braak I/II, significantly increased odds were detected for agitation, anxiety, appetite changes, depression, and sleep disturbances, compared to controls. Increased odds of agitation continue into Braak III/IV. Braak V/VI is associated with higher odds for delusions. No increased odds for neuropsychiatric symptoms were found to correlate with amyloid-beta pathology. Increased odds of neuropsychiatric symptoms are associated with early neurofibrillary tangle pathology, suggesting that subcortical neurofibrillary tangle accumulation with minimal cortical pathology is sufficient to impact quality of life and that neuropsychiatric symptoms are a manifestation of AD biological processes.
Palavras-chave
Alzheimer's disease, amyloid plaques, anxiety, appetite behavior, depression, neurofibrillary tangles, neuropathology, neuropsychiatry, sleep, tau protein
URI
https://observatorio.fm.usp.br/handle/OPI/29836
Referências
  1. Aalten P, 2007, DEMENT GERIATR COGN, V24, P457, DOI 10.1159/000110738
  2. Acosta I, 2018, ALZHEIMERS DEMENT, V14, P271, DOI 10.1016/j.jalz.2017.08.015
  3. Ahima RS, 2008, ENDOCRIN METAB CLIN, V37, P811, DOI 10.1016/j.ecl.2008.08.005
  4. Andres-Benito P, 2017, NEUROPATH APPL NEURO, V43, P373, DOI 10.1111/nan.12386
  5. Anor CJ, 2017, NEURODEGENER DIS, V17, P127, DOI 10.1159/000455127
  6. Apostolova LG, 2007, DEMENT GERIATR COGN, V24, P91, DOI 10.1159/000103914
  7. Assal F, 2002, CURR OPIN NEUROL, V15, P445, DOI 10.1097/00019052-200208000-00007
  8. BELESLIN DB, 1981, BRAIN RES BULL, V6, P285, DOI 10.1016/S0361-9230(81)80060-3
  9. Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096
  10. Bensamoun D, 2016, J ALZHEIMERS DIS, V49, P387, DOI 10.3233/JAD-150181
  11. Blay SL, 2014, INT CLIN PSYCHOPHARM, V29, P157, DOI 10.1097/YIC.0000000000000008
  12. Boublay N, 2016, EUR J NEUROL, V23, P1500, DOI 10.1111/ene.13076
  13. Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0
  14. BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
  15. Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z
  16. Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379
  17. Braak H, 2011, ACTA NEUROPATHOL, V121, P171, DOI 10.1007/s00401-010-0789-4
  18. Bresch A, 2017, APPETITE, V117, P270, DOI 10.1016/j.appet.2017.06.020
  19. Bruen PD, 2008, BRAIN, V131, P2455, DOI 10.1093/brain/awn151
  20. CHARNEY DS, 1983, NEUROPHARMACOLOGY, V22, P1531, DOI 10.1016/0028-3908(83)90122-3
  21. Charney DS, 1998, NEUROSCIENTIST, V4, P35, DOI 10.1177/107385849800400111
  22. Chung S, 2017, NATURE, V545, P477, DOI 10.1038/nature22350
  23. CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308
  24. D'Anna L, 2017, NEURODEGENER DIS, V17, P227, DOI 10.1159/000474940
  25. DaRocha-Souto B, 2011, J NEUROPATH EXP NEUR, V70, P360, DOI 10.1097/NEN.0b013e318217a118
  26. Donovan NJ, 2018, AM J PSYCHIAT, V175, P530, DOI 10.1176/appi.ajp.2017.17040442
  27. Edwards ER, 2009, INT J GERIATR PSYCH, V24, P716, DOI 10.1002/gps.2187
  28. Ehrenberg AJ, 2017, NEUROPATH APPL NEURO, V43, P393, DOI 10.1111/nan.12387
  29. Eslinger PJ, 2012, BEHAV NEUROL, V25, P127, DOI 10.3233/BEN-2011-0351
  30. Eurelings LSM, 2015, INT PSYCHOGERIATR, V27, P639, DOI 10.1017/S1041610214002683
  31. Ferretti Renata Eloah de Lucena, 2010, Dement. neuropsychol., V4, P138, DOI 10.1590/S1980-57642010DN40200011
  32. FORSTL H, 1992, PSYCHOL MED, V22, P877
  33. Frosch MP, 2017, NEUROPATH APPL NEURO, V43, P371, DOI 10.1111/nan.12400
  34. Gallagher D, 2011, INT J GERIATR PSYCH, V26, P166, DOI 10.1002/gps.2509
  35. Ganguli M, 2006, ARCH GEN PSYCHIAT, V63, P153, DOI 10.1001/archpsyc.63.2.153
  36. Gatchel JR, 2017, J ALZHEIMERS DIS, V59, P975, DOI 10.3233/JAD-170001
  37. Gatchel JR, 2017, AM J GERIAT PSYCHIAT, V25, P683, DOI 10.1016/j.jagp.2016.12.017
  38. Geerts H, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00047
  39. GERMAN DC, 1987, NEUROSCIENCE, V21, P305, DOI 10.1016/0306-4522(87)90123-0
  40. Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01
  41. GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106
  42. Gotter AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27147
  43. Green RC, 2003, ARCH NEUROL-CHICAGO, V60, P753, DOI 10.1001/archneur.60.5.753
  44. Grinberg Lea Tenenholz, 2007, Cell and Tissue Banking, V8, P151, DOI 10.1007/s10561-006-9022-z
  45. Guadagna S, 2012, NEUROBIOL AGING, V33, P2798, DOI 10.1016/j.neurobiolaging.2012.01.015
  46. Gualtieri CT, 2008, PROG NEURO-PSYCHOPH, V32, P962, DOI 10.1016/j.pnpbp.2007.12.030
  47. Guimaraes HC, 2008, ARQ NEURO-PSIQUIAT, V66, P436, DOI 10.1590/S0004-282X2008000300035
  48. Holzschneider Kathrin, 2011, Dialogues Clin Neurosci, V13, P453
  49. Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018
  50. Jimenez JC, 2018, NEURON, V97, P670, DOI 10.1016/j.neuron.2018.01.016
  51. Kai K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133666
  52. Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962
  53. Karran E, 2016, J NEUROCHEM, V139, P237, DOI 10.1111/jnc.13632
  54. Kessing LV, 2004, J NEUROL NEUROSUR PS, V75, P1662, DOI 10.1136/jnnp.2003.031773
  55. Klatka LA, 1996, NEUROLOGY, V47, P1148, DOI 10.1212/WNL.47.5.1148
  56. Krishnan V, 2008, NATURE, V455, P894, DOI 10.1038/nature07455
  57. Lanctot KL, 2017, ALZHEIMERS DEMENT, V3
  58. Li XL, 2014, BIOMED RES INT, DOI 10.1155/2014/927804
  59. Lucey BP, 2015, NAT NEUROSCI, V18, P933, DOI 10.1038/nn.4048
  60. Lyketsos CG, 2011, ALZHEIMERS DEMENT, V7, P328, DOI 10.1016/j.jalz.2011.03.007
  61. Mander BA, 2017, NEURON, V94, P19, DOI 10.1016/j.neuron.2017.02.004
  62. Marshall GA, 2006, DEMENT GERIATR COGN, V21, P144, DOI 10.1159/000090674
  63. McKeith I, 2005, LANCET NEUROL, V4, P735, DOI 10.1016/S1474-4422(05)70219-2
  64. MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479
  65. Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3
  66. Moran M, 2005, SLEEP MED, V6, P347, DOI 10.1016/j.sleep.2004.12.005
  67. Moret Chantal, 2011, Neuropsychiatr Dis Treat, V7, P9, DOI 10.2147/NDT.S19619
  68. Morris JC, 2005, ALZ DIS ASSOC DIS, V19, P163
  69. MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a
  70. NAKAMURA K, 1972, PSYCHOPHARMACOLOGIA, V24, P359, DOI 10.1007/BF00402530
  71. Neary NM, 2004, CLIN ENDOCRINOL, V60, P153, DOI 10.1046/j.1365-2265.2003.01839.x
  72. O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P1091, DOI 10.1001/archneur.65.8.1091
  73. Onyike CU, 2007, AM J GERIAT PSYCHIAT, V15, P365, DOI 10.1097/01.JGP.0000235689.42910.0d
  74. Osorio RS, 2014, CURR PHARM DESIGN, V20, P2547, DOI 10.2174/13816128113199990502
  75. Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530
  76. Pomara N, 2012, AM J PSYCHIAT, V169, P523, DOI 10.1176/appi.ajp.2011.11081153
  77. Rahimi J, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0082-1
  78. Rajan KB, 2015, NEUROLOGY, V85, P898, DOI 10.1212/WNL.0000000000001774
  79. Rapp MA, 2006, ARCH GEN PSYCHIAT, V63, P161, DOI 10.1001/archpsyc.63.2.161
  80. Rapp MA, 2008, AM J GERIAT PSYCHIAT, V16, P168, DOI 10.1097/JGP.0b013e31816029ec
  81. Reeves SJ, 2012, NEUROSCI BIOBEHAV R, V36, P2274, DOI 10.1016/j.neubiorev.2012.08.001
  82. Rosenberg PB, 2015, MOL ASPECTS MED, V43-44, P25, DOI 10.1016/j.mam.2015.05.005
  83. Rothman SM, 2012, NEUROMOL MED, V14, P194, DOI 10.1007/s12017-012-8181-2
  84. Rub U, 2016, CURR ALZHEIMER RES, V13, P1178, DOI 10.2174/1567205013666160606100509
  85. Ruhe HG, 2007, MOL PSYCHIATR, V12, P331, DOI 10.1038/sj.mp.4001949
  86. Savva GM, 2009, BRIT J PSYCHIAT, V194, P212, DOI 10.1192/bjp.bp.108.049619
  87. Schneider JA, 2007, NEUROLOGY, V69, P2197, DOI 10.1212/01.wnl.0000271090.28148.24
  88. Scholl M, 2016, NEURON, V89, P971, DOI 10.1016/j.neuron.2016.01.028
  89. Sehlmeyer C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005865
  90. Seignourel PJ, 2008, CLIN PSYCHOL REV, V28, P1071, DOI 10.1016/j.cpr.2008.02.008
  91. Shinagawa S, 2015, J GERIATR PSYCH NEUR, V28, P99, DOI 10.1177/0891988714554710
  92. SORENSON CA, 1975, PHARMACOL BIOCHEM BE, V3, P331, DOI 10.1016/0091-3057(75)90039-8
  93. Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
  94. Stratmann K, 2016, BRAIN PATHOL, V26, P371, DOI 10.1111/bpa.12289
  95. Suemoto CK, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002267
  96. Takahashi K, 2006, J NEUROSCI, V26, P10292, DOI 10.1523/JNEUROSCI.2341-06.2006
  97. Talakoub O, 2017, ANN CLIN TRANSL NEUR, V4, P897, DOI 10.1002/acn3.466
  98. Tekin S, 2001, ANN NEUROL, V49, P355, DOI 10.1002/ana.72.abs
  99. Theofilas P, 2017, ALZHEIMERS DEMENT, V13, P236, DOI 10.1016/j.jalz.2016.06.2362
  100. van der Linde RM, 2016, BRIT J PSYCHIAT, V209, P368, DOI 10.1192/bjp.bp.114.148403
  101. Vettor R, 2002, J ENDOCRINOL INVEST, V25, P836, DOI 10.1007/BF03344047
  102. VILBERG TR, 1975, PHARMACOL BIOCHEM BE, V3, P377, DOI 10.1016/0091-3057(75)90045-3
  103. Weinshenker D, 2018, TRENDS NEUROSCI, V41, P211, DOI 10.1016/j.tins.2018.01.010
  104. Wilson RS, 2013, JAMA PSYCHIAT, V70, P1320, DOI 10.1001/jamapsychiatry.2013.2224
  105. Wilson RS, 2006, NEUROEPIDEMIOLOGY, V27, P143, DOI 10.1159/000095761
  106. Yaffe K, 2018, JAMA INTERN MED, V178, P281, DOI 10.1001/jamainternmed.2017.7299
  107. Zhao Le-zhang, 2003, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V19, P175
  108. ZWEIG RM, 1988, ANN NEUROL, V24, P233, DOI 10.1002/ana.410240210

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/15
Carregar mais